Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006037 · ClinicalTrials.gov registry record · Phase 2

Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer

A Phase 2 study, sponsored by University of Southern California.

Terminated
Registry status
Phase 2
Development phase
18
Enrollment target

NCT00006037 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 18 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006037, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.

TERMINATED
Registry status
Phase 2
Development phase
18 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known if chemotherapy is more effective with or without IM-862 in treating colorectal cancer. PURPOSE: Randomized phase II trial to study the effectiveness of chemotherapy plus IM-862 in treating patients who have metastatic colorectal cancer.

Interventions

  • DRUG fluorouracil
  • DRUG irinotecan hydrochloride
  • DRUG oglufanide disodium

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 1999-11
Est. Completion 2001-11
Phase Phase 2

Sponsor

University of Southern California

617 total trials

What the Registry Record Tells You About NCT00006037

The ClinicalTrials.gov registry entry for NCT00006037 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.

NCT00006037 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00006037 about?

NCT00006037 is a clinical study titled "Chemotherapy Plus IM-862 in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. IM-862 may stop the growth of colorectal cancer by stopping blood flow to the tumor. It is not yet known if chemotherapy is more effective with or without IM-862 in treating colore...

What is the current status of trial NCT00006037?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 1999-11. Estimated completion is 2001-11.

What interventions are being tested in trial NCT00006037?

The interventions under investigation include: fluorouracil (DRUG), irinotecan hydrochloride (DRUG), oglufanide disodium (DRUG).

Who is sponsoring clinical trial NCT00006037?

This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.